Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD)
NCT04336722
Bile Duct Diseases, Biliary Atresia
Los Angeles, California, United States
View Trial DetailsNCT Number: NCT06184971
This is a multi-center retrospective chart review to compile a data repository of the management and outcomes of children with biliary atresia. Overall, investigators aim to evaluate which specific factors contribute to improved patient outcomes, to help guide potential improvements in patient care and resource utilization.
Looking for future studies?
Notify MeUp to 12 year
All sexes
Observational
Connecticut Children's Medical Center, Hartford, Connecticut, United States
Biliary atresia is quite rare, with only 0.73 cases per 10,000 births in the US. Due to this rarity and the geographical spread of the US, the small number of cases end up being dispersed amongst the various pediatric hospitals, which leads to certain hospitals only encountering an affected patient once per decade. This rarity and dispersion makes biliary atresia difficult for researchers to study: single-institution studies are limited by low power and only provide narrow snapshots, whereas large NIH-sponsored consortia report highly selected outcomes from only the largest or most dedicated centers and have largely excluded New England. This leaves a significant knowledge gap regarding the management and outcomes at more typical hospitals. The purpose of this study is to collect clinical data from all children with biliary atresia at all hospitals providing pediatric surgical care in the Northeast, even very-low-volume hospitals. This is a retrospective study, only involving chart review. There will be no interaction with subjects, intervention, or collection of specimens for the purposes of this study. The data will only include clinical information that was recorded during the normal course of patient care. The subjects will be de-identified before entry into a HIPAA-compliant data repository. This data repository will allow researchers to pool data, to yield adequate statistical power and assess differences in management and outcomes regarding this very rare condition.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 10 years
Patient death
Time frame: 10 years
Need for biliary diversion procedure, including the Kasai portoenterostomy
Time frame: 10 years
Need for liver transplant
Time frame: 6 months
Normalization of serum bilirubin after Kasai procedure
Time frame: 10 years
Serum bilirubin level
Time frame: 10 years
Clinical diagnosis of cholangitis
Time frame: 10 years
Post-operative bleeding requiring transfusion or return to the OR
Time frame: 10 years
Patient presentation to the ED for complication related to biliary atresia
Time frame: 10 years
Frequency and age at most recent follow-up with Pediatric Surgeon and/or Hepatologist
Yale University
Other
Biliary Atresia Research Network Northeast (BARNN)
Acronym: BARNN
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04336722
Bile Duct Diseases, Biliary Atresia
Los Angeles, California, United States
View Trial DetailsNCT07328204
Bile Duct Diseases, Biliary Atresia
Hangzhou, China
View Trial DetailsNCT04524390
Bile Duct Diseases, Biliary Atresia
Phoenix, Arizona, United States
View Trial DetailsNCT02922751
Abnormalities, Multiple, Alagille Syndrome
Los Angeles, California, United States
View Trial Details